SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study.

Mortimer, K; Lesosky, M; García-Marcos, L; Asher, MI; Pearce, N; Ellwood, E; Bissell, K; El Sony, A; Ellwood, P; Marks, GB; et al. Mortimer, K; Lesosky, M; García-Marcos, L; Asher, MI; Pearce, N; Ellwood, E; Bissell, K; El Sony, A; Ellwood, P; Marks, GB; Martínez-Torres, A; Morales, E; Perez-Fernandez, V; Robertson, S; Rutter, CE; Silverwood, RJ; Strachan, DP; Chiang, C-Y; Global Asthma Network Phase I Study Group (2022) The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study. Eur Respir J, 60 (3). ISSN 1399-3003 https://doi.org/10.1183/13993003.02865-2021
SGUL Authors: Strachan, David Peter

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (1MB) | Preview
[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (5MB) | Preview
[img]
Preview
PDF (Supplementary tables and figures) Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (313kB) | Preview

Abstract

AIMS: Asthma, hay fever and eczema are three common chronic conditions. There have been no recent multi-country data on the burden of these three conditions in adults; the aims of this study are to fill this evidence gap. METHODS: The Global Asthma Network Phase I is a multi-country cross-sectional population-based study using the same core methodology as the International Study of Asthma and Allergies in Childhood Phase III. It provides data on the burden of asthma, hay fever and eczema in children and adolescents, and, for the first time, in their parents/guardians. RESULTS: Data were available from 193 912 adults (104 061 female; mean±sd age 38±7.5 years) in 43 centres in 17 countries. The overall prevalence (range) of symptoms was 6.6% (0.9-32.7%) for current wheeze, 4.4% (0.9-29.0%) for asthma ever, 14.4% (2.8-45.7%) for hay fever ever and 9.9% (1.6-29.5%) for eczema ever. Centre prevalence varied considerably both between countries and within countries. There was a moderate correlation between hay fever ever and asthma ever, and between eczema ever and hay fever ever at the centre level. There were moderate to strong correlations between indicators of the burden of disease reported in adults and the two younger age groups. CONCLUSION: We found evidence for a substantial burden of asthma, hay fever ever and eczema ever in the countries examined, highlighting the major public health importance of these diseases. Prevention strategies and equitable access to effective and affordable treatments for these three conditions would help mitigate the avoidable morbidity they cause.

Item Type: Article
Additional Information: Copyright © The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Keywords: Adolescent, Adult, Asthma, Child, Cross-Sectional Studies, Eczema, Female, Humans, Middle Aged, Prevalence, Rhinitis, Allergic, Seasonal, Surveys and Questionnaires, Global Asthma Network Phase I Study Group, Humans, Asthma, Eczema, Prevalence, Cross-Sectional Studies, Adolescent, Adult, Middle Aged, Child, Female, Rhinitis, Allergic, Seasonal, Surveys and Questionnaires, 11 Medical and Health Sciences, Respiratory System
SGUL Research Institute / Research Centre: Academic Structure > Population Health Research Institute (INPH)
Journal or Publication Title: Eur Respir J
ISSN: 1399-3003
Language: eng
Dates:
DateEvent
15 September 2022Published
24 February 2022Published Online
3 February 2022Accepted
Publisher License: Publisher's own licence
Projects:
Project IDFunderFunder ID
UNSPECIFIEDInternational Union Against Tuberculosis and Lung DiseaseUNSPECIFIED
UNSPECIFIEDBoehringer Ingelheim NZUNSPECIFIED
UNSPECIFIEDAstraZenecahttp://dx.doi.org/10.13039/100004325
MR/N013638/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
668954Seventh Framework Programmehttp://dx.doi.org/10.13039/501100004963
PI17/0170Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
NAF\R2\180681Academy of Medical Scienceshttp://dx.doi.org/10.13039/501100000691
16/136/35National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
PubMed ID: 35210319
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114110
Publisher's version: https://doi.org/10.1183/13993003.02865-2021

Actions (login required)

Edit Item Edit Item